{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ESTRING&page=5", "query": { "intervention": "ESTRING", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 887, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ESTRING&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ESTRING&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:26:24.980Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00420342", "title": "Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postmenopause", "Hypertension", "Pre-Hypertension" ], "interventions": [ { "name": "Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)", "type": "DRUG" }, { "name": "SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "45 Years to 65 Years · Female only" }, "enrollment_count": 92, "start_date": "2007-01", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2015-06-02", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 9, "location_summary": "Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Paw Paw", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420342" }, { "nct_id": "NCT04553133", "title": "PF-07104091 as a Single Agent and in Combination Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "PF-07104091 monotherapy dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + palbociclib + fulvestrant", "type": "DRUG" }, { "name": "PF-07104091 + palbociclib + letrozole", "type": "DRUG" }, { "name": "PF-07104091 monotherapy dose expansion (ovarian)", "type": "DRUG" }, { "name": "PF-07104091 monotherapy dose expansion (SCLC)", "type": "DRUG" }, { "name": "PF-07104091 + Fulvestrant (post CDK4/6)", "type": "DRUG" }, { "name": "PF-0704091 + Fulvestrant (post CDK4/6)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2020-09-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 17, "location_summary": "Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more", "locations": [ { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553133" }, { "nct_id": "NCT03097120", "title": "The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Disease" ], "interventions": [ { "name": "0.625 mg of conjugated equine estrogen", "type": "DRUG" }, { "name": "0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate", "type": "DRUG" }, { "name": "placebo tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "FEMALE", "summary": "55 Years and older · Female only" }, "enrollment_count": 309, "start_date": "1995-01", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03097120" }, { "nct_id": "NCT05305924", "title": "Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ER-Positive Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Fulvestrant Run-In", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-02-25", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05305924" }, { "nct_id": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2020-12-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 9, "location_summary": "Commack, New York • Harrison, New York • New York, New York + 5 more", "locations": [ { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Uniondale", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04556773" }, { "nct_id": "NCT06785129", "title": "Endometriosis and Migraine", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Migraine", "Endometriosis" ], "interventions": [ { "name": "Thermal stimuli", "type": "DEVICE" }, { "name": "Pressure stimuli", "type": "DEVICE" }, { "name": "Pain ratings", "type": "BEHAVIORAL" }, { "name": "Conditioned pain modulation (CPM) response", "type": "BEHAVIORAL" }, { "name": "Hormonal assessment", "type": "BIOLOGICAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "12 Years to 45 Years · Female only" }, "enrollment_count": 120, "start_date": "2025-02-12", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06785129" }, { "nct_id": "NCT01903031", "title": "Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Nuvaring", "type": "DEVICE" }, { "name": "EFV", "type": "DRUG" }, { "name": "ATV/r", "type": "DRUG" }, { "name": "TDF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2014-12-30", "completion_date": "2016-10-10", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903031" }, { "nct_id": "NCT02215395", "title": "An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Antifungal Drug Adverse Reaction" ], "interventions": [ { "name": "NES/EE CVR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Population Council", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 45, "start_date": "2014-03", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2017-08-15", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "Springfield, Missouri", "locations": [ { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02215395" }, { "nct_id": "NCT06250205", "title": "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Obicetrapib", "type": "DRUG" }, { "name": "Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)", "type": "DRUG" }, { "name": "Drospirenone / Ethinyl Estradiol (COC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 30, "start_date": "2024-02-05", "completion_date": "2024-04-26", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06250205" }, { "nct_id": "NCT00722761", "title": "Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "drospirenone and ethinyl estradiol", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-03-05", "last_synced_at": "2026-10-26T03:26:24.980Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722761" } ] }